There is evidence that COVID-19 patients develop resistance to exogenous fibrinolytics [441,442,443], which may be due not only to the suppression of factors involved in plasminogen activation, but also to increased activity of fibrinolysis inhibitors. Here, PLG is linked to COVID-19.